<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112483">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01722266</url>
  </required_header>
  <id_info>
    <org_study_id>NN1962</org_study_id>
    <nct_id>NCT01722266</nct_id>
  </id_info>
  <brief_title>Liraglutide in the Treatment of Type 1 Diabetes Mellitus</brief_title>
  <official_title>Liraglutide in the Treatment of Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaleida Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaleida Health</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis 1: Treatment with Liraglutide in patients with type 1 diabetes decreases fasting,
      postprandial and the overall mean glucose concentrations.

      Aim 1.1: To compare the mean fasting, the mean weekly glucose and the standard deviation of
      weekly blood glucose concentrations as recorded by continuous glucose monitoring prior to
      and following 6 weeks and 12 weeks of treatment with 0.6, 1.2 and 1.8 mg of liraglutide
      daily. In addition, the time spent at glucose concentrations &gt;150 and 200mg/dl and &lt;70 and
      &lt;40 mg/dl will also be compared.

      Aim 1.2: To compare the postprandial glucose concentrations following a test meal before and
      after 12 weeks of treatment with 0.6, 1.2 and 1.8 mg of liraglutide daily.  Glucose
      concentrations will be measured as areas under the curve for the data obtained from the meal
      challenge.

      Aim 1.3: To compare HbA1c levels before and after 12 weeks of treatment with 0.6, 1.2 and
      1.8 mg of liraglutide daily Hypothesis 2: Treatment with Liraglutide in patients with type 1
      diabetes decreases postprandial glucagon concentrations and increases postprandial C-peptide
      concentrations.

      Aim 2.1: To compare fasting and postprandial glucagon and C-peptide concentrations following
      a test meal before and after 12 weeks of treatment with 0.6, 1.2 and 1.8 mg of liraglutide
      daily.

      Hypothesis 3: Treatment with Liraglutide in patients with type 1 diabetes delays gastric
      emptying.

      Aim 3.1: To compare the gastric emptying as measured by acetaminophen absorption before and
      after 12 weeks of treatment with 0.6, 1.2 and 1.8 mg of liraglutide daily.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean weekly glucose concentrations.</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary endpoint of the study is to detect a difference from baseline in mean weekly blood glucose concentrations before and after 12 weeks of treatment in each of the Liraglutide groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide 1.8mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide 1.2mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide 0.6 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <arm_group_label>Liraglutide 1.8mg</arm_group_label>
    <arm_group_label>Liraglutide 1.2mg</arm_group_label>
    <arm_group_label>Liraglutide 0.6 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with type 1 diabetes mellitus: Fasting c-peptide &lt; 0.1nmol/l on insulin
             therapy for more than 12 months with or without history of diabetic ketoacidosis.

          2. Using a continuous glucose monitoring device (CGM) and regularly measuring their
             blood sugars four times daily

          3. HbA1c of less than 8.5%.

          4. Well versed with carbohydrate counting

          5. Age 18-75 years

        Exclusion Criteria:

          1. Type 1 diabetes for less than 12 months;

          2. Coronary event or procedure (myocardial infarction, unstable angina, coronary artery
             bypass, surgery or coronary angioplasty) in the previous four weeks;

          3. Hepatic disease (transaminase &gt; 3 times normal) or cirrhosis;

          4. Renal impairment (serum creatinine &gt; 1.5);

          5. HIV or Hepatitis C positive status;

          6. Participation in any other concurrent clinical trial;

          7. Any other life-threatening, non-cardiac disease;

          8. Use of an investigational agent or therapeutic regimen within 30 days of study.

          9. history of pancreatitis

         10. pregnancy

         11. inability to give informed consent

         12. history of gastroparesis

         13. history of medullary thyroid carcinoma or MEN 2 syndrome.

         14. Family history of MEN 2, Family history of medullary thyroid cancer, or familial
             medullary thyroid cancer

         15. Women of childbearing potential who are not using adequate contraception 16) Women
             who are pregnant
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paresh Dandona, MBBS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaleida Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sonja Williams</last_name>
    <phone>716-626-7998</phone>
    <email>swilliams@kaleidahealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeanne Hejna</last_name>
    <phone>716-626-7998</phone>
    <email>jhejna@kaleidahealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Diabetes-Endocrinology Center of Western NY</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonja Williams</last_name>
      <phone>716-626-7998</phone>
    </contact>
    <investigator>
      <last_name>Paresh Dandon, MBBS,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 5, 2012</lastchanged_date>
  <firstreceived_date>November 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaleida Health</investigator_affiliation>
    <investigator_full_name>Paresh Dandona, MD</investigator_full_name>
    <investigator_title>Distinguished Professor of Medicine</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
